Literature DB >> 15297310

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.

Manik Chatterjee1, Thorsten Stühmer, Pia Herrmann, Kurt Bommert, Bernd Dörken, Ralf C Bargou.   

Abstract

The interleukin-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) pathway contributes to the pathogenesis of multiple myeloma (MM) and protects MM cells from apoptosis. However, MM cells survive the IL-6R blockade if they are cocultured with bone marrow stromal cells (BMSCs), suggesting that the BM microenvironment stimulates IL-6-independent pathways that exert a pro-survival effect. The goal of this study was to investigate the underlying mechanism. Detailed pathway analysis revealed that BMSCs stimulate STAT3 via the IL-6R, and mitogen-activated protein (MAP) kinases via IL-6R-independent mechanisms. Abolition of MEK1,2 activity with PD98059, or ERK1,2 small interfering RNA knockdown, was insufficient to induce apoptosis. However, the combined disruption of the IL-6R/STAT3 and MEK1,2/ERK1,2 pathways led to strong induction of apoptosis even in the presence of BMSCs. This effect was observed with MM cell lines and with primary MM cells, suggesting that the BMSC-induced activation of MEK1,2/ERK1,2 renders MM cells IL-6R/STAT3 independent. Therefore, in the presence of cells from the BM micro-environment, combined targeting of different (and independently activated) pathways is required to efficiently induce apoptosis of MM cells. This might have direct implications for the development of future therapeutic strategies for MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297310     DOI: 10.1182/blood-2004-04-1670

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Authors:  Courtney L Jones; Christy M Gearheart; Susan Fosmire; Cristina Delgado-Martin; Nikki A Evensen; Karen Bride; Angela J Waanders; Faye Pais; Jinhua Wang; Teena Bhatla; Danielle S Bitterman; Simone R de Rijk; Wallace Bourgeois; Smita Dandekar; Eugene Park; Tamara M Burleson; Pillai Pallavi Madhusoodhan; David T Teachey; Elizabeth A Raetz; Michelle L Hermiston; Markus Müschen; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Michael J Garabedian; Christopher C Porter; William L Carroll
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

Review 2.  MicroRNA-21 and multiple myeloma: small molecule and big function.

Authors:  Jing Ma; Su Liu; Yafei Wang
Journal:  Med Oncol       Date:  2014-07-01       Impact factor: 3.064

3.  The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Authors:  Manik Chatterjee; Mindaugas Andrulis; Thorsten Stühmer; Elisabeth Müller; Claudia Hofmann; Torsten Steinbrunn; Tanja Heimberger; Heike Schraud; Stefanie Kressmann; Hermann Einsele; Ralf C Bargou
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

4.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

5.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

6.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

7.  NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

Authors:  Chiara Ambrogio; Cinzia Martinengo; Claudia Voena; Fabrizio Tondat; Ludovica Riera; Paola Francia di Celle; Giorgio Inghirami; Roberto Chiarle
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 8.  Recent advances in antimultiple myeloma drug development.

Authors:  Nuozhou Wang; Patrick Bartlow; Qin Ouyang; Xiang-Qun Xie
Journal:  Pharm Pat Anal       Date:  2014-05

9.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

10.  Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.

Authors:  A Ramírez-Labrada; N López-Royuela; V Jarauta; P Galán-Malo; G Azaceta; L Palomera; J Pardo; A Anel; I Marzo; J Naval
Journal:  Clin Transl Oncol       Date:  2014-07-19       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.